Evidence map›Paper›PMID 42602175›Full record

ArticleFrontiers in immunology2026

TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report.

Jinlin Zhang, Li Ma, Xiu Liu, Yuxin An, Mohan Zhao, Mengnan Li, Xiaomei Zhang, Jile Liu, Rui Zhang, Mingfeng Zhao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinlin Zhang *First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Li Ma *Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xiu Liu *First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Yuxin AnDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Mohan ZhaoFirst Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Mengnan LiSchool of Medicine, Nankai University, Tianjin, China.
Xiaomei ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Jile LiuFirst Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Rui ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Mingfeng ZhaoTianjin Thrombosis and Hemostasis Institute, Department of Hematology, Tianjin First Central Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a pivotal therapeutic strategy for refractory/relapsed hematologic malignancies. Sequential therapy with CD7 chimeric antigen receptor T (CAR-T) cells combined with allo-HSCT provides a novel therapeutic approach for T-lymphoid malignancies, CD7-highly expressed acute myeloid leukemia (AML), and mixed phenotype acute leukemia (MPAL). This strategy circumvents the toxicities of conventional myeloablative conditioning chemotherapy and immunosuppressive agents, while achieving tumor eradication, hematopoietic reconstitution, and prevention of graft-versus-host disease (GVHD). Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but life-threatening complication following allo-HSCT, associated with elevated non-relapse mortality (NRM). This article reports a case of early-onset TA-TMA in a patient with MPAL after CD7 CAR-T bridging to allo-HSCT. This study aims to enhance clinicians' awareness of the diagnosis and management of TA-TMA following CAR-T bridging to allo-HSCT, provide a reference for early identification and timely intervention, and further improve patient outcomes.

Indexed as

Antigens, CD7Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveLeukemia, Biphenotypic, AcuteThrombotic MicroangiopathiesFemaleHumansMiddle AgedReceptors, Chimeric AntigenTransplantation, HomologousAntigens, CD7Receptors, Chimeric Antigenallogeneic hematopoietic stem cell transplantationCD7 CAR-T cellseculizumabmixed phenotype acute leukemiatransplant-associated thrombotic microangiopathy

Identifiers

PMID42602175
PMCPMC13473368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.